Screening for Early Diagnosis of Nose Cancer
- Conditions
- Nasopharyngeal Carcinoma
- Registration Number
- NCT07019870
- Lead Sponsor
- National University Hospital, Singapore
- Brief Summary
The goal of this clinical trial is to evaluate the effectiveness of screening in identifying nasopharyngeal cancer (NPC), and evaluate the performance of Epstein-Barr virus (EBV) biomarkers in a community screening setting in Singapore.
Participants will assessed for their risk of NPC using EBV Early Antigen (EA) IgA serology and cell-free plasma EBV DNA. If the initial plasma EBV DNA test is positive, a repeat blood sample will be taken and tested. Saliva will also be collected for evaluation of EBV risk strains, but not used for risk evaluation.
1. High risk individuals are determined by:
* a positive EBV EA IgA serology test, and/or
* two consecutive positive plasma EBV DNA tests
High risk individuals will undergo evaluation in the outpatient Otolaryngology clinic. The evaluation includes a head and neck examination, nasoendoscopy and nasopharyngeal biopsy. Clinical data will be collected at yearly intervals, for at least 3 years, with annual clinical examination and blood tests.
2. Low risk individuals are determined by:
* a negative EBV EA IgA serology, and
* a negative plasma EBV DNA test, or an initially positive plasma EBV DNA test followed by a negative plasma EBV DNA test on repeat blood taking.
Low risk individuals will be contacted via phone call every year for at least 3 years to confirm their disease status. Records will also be reviewed at the National Registry of Disease Office, Health Promotion Board, to confirm that the participant has not been diagnosed with nasopharyngeal cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20000
- Chinese, Malay, and mixed ethnicities
- individuals not diagnosed with NPC
- individuals with family history of NPC
- younger than 35, older than 60
- individuals already diagnosed with NPC
- pregnant women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Stage distribution of NPC From enrollment of the participant to follow-up at three years Stage distribution of NPC diagnosed in study participants, compared to stage distribution of NPC in unscreened individuals routinely diagnosed in the clinic.
Accuracy of EBV IgA serology in identifying NPC cases From enrollment of the participant to follow-up at three years Accuracy of EBV IgA serology including sensitivity, specificity, positive predictive value and negative predictive value
Accuracy of plasma EBV DNA in identifying NPC cases From enrollment of the participant to follow-up at three years Accuracy of plasma EBV DNA including sensitivity, specificity, positive predictive value and negative predictive value
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
National University Hospital
🇸🇬Singapore, Singapore
National University Polyclinics
🇸🇬Singapore, Singapore
National University Hospital🇸🇬Singapore, SingaporeSerene SiowContact(65) 6772 3850entsch@nus.edu.sg